BecampanelAlternative Names: AMP 397; AMP 397A
Latest Information Update: 22 Jul 2010
At a glance
- Originator Novartis
- Class Antiepileptic drugs; Quinoxalines; Small molecules
- Mechanism of Action AMPA receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Epilepsy